Allogene <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Initiates Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma
Allogene Therapeutics Inc., a clinical-stage biotechnology company specializing in allogeneic CAR T products, has announced updates on several key clinical trials. The pivotal Phase 2 ALPHA3 trial with Cemacabtagene Ansegedleucel (Cema-Cel) is progressing as a two-arm randomized study in first-line consolidation for large B-cell lymphoma, with more than 50 sites activated in the U.S. and Canada, and international expansion underway. A scheduled futility analysis is on track for the first half of 2026. Additionally, the company has initiated the Phase 1 RESOLUTION trial with ALLO-329 for autoimmune diseases, with proof-of-concept data expected in the first half of 2026. The Phase 1 TRAVERSE trial with ALLO-316 in renal cell carcinoma is also underway. Allogene will host a live conference call and webcast to discuss these developments and financial results, with a replay available on their website for 30 days following the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001737287-25-000087), on August 13, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。